Sy
Non verificato

Syros Pharmaceuticals

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute
12/11/2024
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Oncologia
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
1.00
31/10/2024
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
1.00
24/10/2024
Mercato azionario
Finanza
Web e Social Network
Telefonia e Varie
Biotecnologia
Salute
Farmaceutica
Cardiologia
Oncologia
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
1.00
27/08/2024
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Eventi
Web e Social Network
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
1.00
12/08/2024
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
1.00
31/07/2024
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Web e Social Network
Telefonia e Varie
Mercato azionario
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update
1.00
24/07/2024
Biotecnologia
Farmaceutica
Salute
Oncologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0